TRAM1

TRAM1 is an ER-resident membrane protein that supports the translocation, quality control, and stress responses of secretory and membrane proteins, and that secondarily acts as a ligand-dependent nuclear receptor coactivator (PMID:9346901, PMID:19121997, PMID:32013668). As a coactivator, it binds thyroid hormone receptor, androgen receptor, and glucocorticoid receptor in a ligand-dependent manner and enhances their transcriptional output; notably, it engages TR through subdomains outside the canonical AF-2 surface, interacting even with an AF-2 mutant that abolishes SRC-1 binding, and it stimulates both DHT-dependent and constitutive AR N-terminal/DNA-binding-domain activity (PMID:9346901, PMID:10965917). At the ER membrane, TRAM1 promotes the dislocation of misfolded membrane proteins during ERAD: it complexes with Derlin-1 and signal peptide peptidase and with the viral US2 and US11 proteins, and its loss stabilizes glycosylated MHC class I heavy chains and impairs degradation of membrane substrates such as Cln6(M241T) and US2 while leaving soluble ERAD substrates unaffected (PMID:19121997, PMID:20430023). TRAM1 also assists translocation of a subset of nascent ER clients; it does not act as a cytosolic signal-peptide/TMH receptor or alter Sec61-channel open probability, but instead acts at the lipid bilayer adjacent to the Sec61 lateral gate (PMID:32013668). Consistent with its role in ER homeostasis, TRAM1 depletion hyperactivates the unfolded protein response and downstream signaling: in hepatocytes it sits upstream of an ER stress–JNK–Akt axis governing insulin signaling (PMID:25600807), and in microglia it cooperates with TLR4 to drive IRAK1/TBK1/IRF3 activation and p65-NF-κB nuclear translocation promoting M1 polarization (PMID:26563450). TRAM1 is additionally co-opted at ER-derived membranes by SARS-CoV-2, where a REEP5/TRAM1 complex interacts with NSP3 to support viral replication (PMID:37768083).

1. 1997 High

   Established TRAM1's first known function as a nuclear receptor coactivator and showed it engages thyroid hormone receptor through a non-canonical surface distinct from SRC-1.

   Evidence Far-Western expression screening, ligand-dependent binding with AF-2 and helix-3 LBD mutants, and transactivation assays

   PMID:9346901

   Open questions at the time

   • The structural basis for AF-2-independent TR binding was not defined
   • Did not address TRAM1's ER membrane localization or membrane function
2. 2000 High

   Extended the coactivator role to steroid receptors by mapping ligand-dependent binding to multiple AR domains and demonstrating functional enhancement of AR and GR transactivation.

   Evidence Yeast two-hybrid, GST pulldown with domain constructs, and co-transfection transactivation assays

   PMID:10965917

   Open questions at the time

   • Did not reconcile nuclear coactivator activity with ER membrane residence
   • No in vivo evidence for receptor regulation
3. 2009 High

   Defined TRAM1 as an ERAD dislocation factor by showing it complexes with degradation intermediates and dislocation machinery and is required for viral US2/US11-driven removal of class I heavy chains.

   Evidence Reciprocal Co-IP, siRNA knockdown, and pulse-chase in cells expressing HCMV US2/US11

   PMID:19121997

   Open questions at the time

   • Mechanism by which TRAM1 couples to Derlin-1/SPP not resolved
   • Endogenous (non-viral) substrate repertoire not defined
4. 2010 Medium

   Showed TRAM1's ERAD role is substrate-selective for membrane-localized misfolded proteins and that its loss heightens the UPR and NF-κB activity.

   Evidence Knockdown cells with UPRE/NF-κB reporters and degradation assays across membrane vs soluble substrates

   PMID:20430023

   Open questions at the time

   • What confers selectivity for membrane over soluble substrates is unknown
   • Link between ERAD defect and UPR/NF-κB activation not mechanistically traced
5. 2015 Medium

   Connected TRAM1 to inflammatory signaling, placing it as a required component of TLR4-driven NF-κB activation and M1 microglia polarization.

   Evidence Gain- and loss-of-function with Western blotting of signaling intermediates and NF-κB translocation in BV2 cells and primary microglia

   PMID:26563450

   Open questions at the time

   • Direct physical link between TRAM1 and TLR4 adapters not shown
   • Relationship to TRAM1's ER membrane function unclear
6. 2015 Medium

   Positioned TRAM1 upstream of an ER stress–JNK–Akt axis controlling hepatic insulin signaling, defining pathway order via pharmacological rescue.

   Evidence siRNA knockdown, ER stress and JNK/Akt Western blotting, JNK-inhibitor rescue, and glucose uptake in HepG2 cells

   PMID:25600807

   Open questions at the time

   • Molecular trigger linking TRAM1 loss to CHOP/GRP78 induction not identified
   • In vivo metabolic relevance not tested
7. 2020 Medium

   Refined the translocation mechanism by excluding a cytosolic SP/TMH receptor role and Sec61 gating effect, pointing instead to bilayer modulation near the lateral gate.

   Evidence Label-free proteomics after depletion, live-cell ER calcium imaging, and bioinformatic SP/TMH analysis in HeLa cells

   PMID:32013668

   Open questions at the time

   • Direct evidence for lipid-bilayer modulation not provided
   • No structural feature explaining client selectivity identified
8. 2023 Medium

   Identified TRAM1 as a host factor co-opted by SARS-CoV-2, with a REEP5/TRAM1 complex binding NSP3 at replication organelles to promote replication.

   Evidence Host-viral interactome mapping and viral replication assays

   PMID:37768083

   Open questions at the time

   • Whether TRAM1 is required versus incidental to replication not dissected
   • Stoichiometry and architecture of the REEP5/TRAM1/NSP3 assembly unknown
9. 2025 Low

   Implicated TRAM1 as a direct ceramide-binding mediator of ER-stress-driven lethal signaling in endocrine-therapy-resistant breast cancer.

   Evidence Photoactivatable ceramide probe pulldown plus siRNA knockdown with cell-death and PERK-pathway readouts (preprint)

   PMID:bio_10.1101_2025.08.18.670862

   Open questions at the time

   • Preprint, single lab, without full mechanistic reconstitution
   • Ceramide-binding site on TRAM1 not mapped
   • Causal link between ceramide binding and PERK activation not established

• How TRAM1's membrane-embedded ER functions (translocation, ERAD dislocation, lipid sensing) mechanistically relate to its reported nuclear coactivator activity and its diverse stress/inflammatory outputs remains unresolved.
• No structure of TRAM1 or its complexes
• No defined biochemical determinant of substrate or lipid selectivity
• Mechanistic bridge between a single ER membrane protein and coactivator, ERAD, TLR4, and ceramide roles is unestablished